Last reviewed · How we verify
JK-1201I
JK-1201I is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
JK-1201I is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | JK-1201I |
|---|---|
| Also known as | PEG-Irinotecan |
| Sponsor | JenKem Technology Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Endocrinology/Metabolic Disease |
| Phase | Phase 3 |
Mechanism of action
JK-1201I activates glucagon-like peptide-1 (GLP-1) receptors, which enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety. As a long-acting formulation, it provides sustained therapeutic effects with less frequent dosing compared to shorter-acting GLP-1 agonists, making it suitable for chronic management of type 2 diabetes and obesity.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
- JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) (PHASE2)
- JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases (PHASE2)
- Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor (PHASE1)
- JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer (PHASE3)
- Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JK-1201I CI brief — competitive landscape report
- JK-1201I updates RSS · CI watch RSS
- JenKem Technology Co., Ltd. portfolio CI